{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:30:28Z","timestamp":1730871028541,"version":"3.28.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>\n     Zusammenfassung\n    <\/jats:title><jats:p>\n   Die Hyperkalz\u00e4mie ist eine lebensbedrohliche Elektrolytentgleisung, die nicht nur im Rahmen einer endokrinologischen Erkrankung auftritt, sondern auch h\u00e4ufig mit einem Tumorleiden assoziiert ist. Der Schweregrad wird bestimmt durch die H\u00f6he der Normabweichung, die Akuit\u00e4t des Auftretens und die Schwere der Symptomatik. Die Symptome sind unspezifisch, k\u00f6nnen jedes Organsystem betreffen und letztendlich in einer lebensbedrohlichen hyperkalz\u00e4mischen Krise resultieren, die durch eine Herzrhythmusst\u00f6rung, metabolische Azidose, Exsikkose, Fieber, psychotische Zust\u00e4nde und letztlich Koma gekennzeichnet ist.\n    <\/jats:p><jats:p>\n   F\u00fcr die Entstehung der Hyperkalz\u00e4mie k\u00f6nnen endokrinologische St\u00f6rungen, Medikamente wie Vitamin D3, Vitamin A, Checkpointinhibitoren, aber auch Malignome urs\u00e4chlich sein. Bis zu 30% der Tumorpatienten sind von der Hyperkalz\u00e4mie betroffen. Diese ist mit einer schlechten Prognose und mit hoher Tumorlast assoziiert. Haupts\u00e4chlich wir die maligne Hyperkalz\u00e4mie durch das sog. PTHrP (parathormon related peptide) verursacht, dass durch die Tumorzellen sezerniert wird.\n    <\/jats:p><jats:p>\n    Bei onkologischen Patienten sollte regelm\u00e4\u00dfig das Serumkalzium (ionisiertes Kalzium und nicht-ionisiertes Kalzium) bestimmt werden. Da der Serumkalziumwert von der Albuminkonzentration abh\u00e4ngig ist, sollte auch dessen Konzentration im Serum bestimmt werden.\n    <\/jats:p><jats:p>\n    Therapeutisch stehen die Erh\u00f6hung des intravesikalen Volumens sowie die Erh\u00f6hung der Kalziumsausscheidung und Inhibition der Kalziumreabsorption im Vordergrund.\n    <\/jats:p>","DOI":"10.1055\/a-2201-6428","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T23:36:32Z","timestamp":1707435392000},"page":"54-59","source":"Crossref","is-referenced-by-count":0,"title":["Die Hyperkalz\u00e4mie \u2013 Intensivmedizin oder Normalstation"],"prefix":"10.1055","volume":"55","author":[{"given":"Jenny","family":"Mauch","sequence":"additional","affiliation":[{"name":"Urologie, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Cascetta","sequence":"additional","affiliation":[{"name":"Urologie, Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes, Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"AF Stewart","year":"2005","journal-title":"N Engl J Med"},{"isbn-type":"print","volume-title":"Herold: Internistische Intensivmedizin","year":"2016","key":"ref2","ISBN":"http:\/\/id.crossref.org\/isbn\/9783000329494"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"H Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3390\/cancers15020529","article-title":"Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma","volume":"15","author":"RM Paragliola","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5811\/westjem.2018.12.37335","article-title":"Diagnosis and Management of Oncologic Emergencies","volume":"20","author":"S Klemencic","year":"2019","journal-title":"West J Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-Related Hypercalcemia","volume":"12","author":"W Goldner","year":"2016","journal-title":"J Oncol Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ecl.2021.07.003","article-title":"Hypercalcemia of Malignancy","volume":"50","author":"MI Hu","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref8","first-page":"216","article-title":"Paraneoplastic manifestations of renal cell carcinoma","volume":"14","author":"PJ Gold","year":"1996","journal-title":"Semin Urol Oncol"},{"key":"ref9","first-page":"99","article-title":"Evaluation and therapy of hypercalcemia","volume":"108","author":"N Khoury","year":"2011","journal-title":"Mo Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ki.1990.87","article-title":"Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury","volume":"37","author":"S Rosen","year":"1990","journal-title":"Kidney Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.0954-6820.1978.tb14879.x","article-title":"Reversible renal failure caused by hypercalcemia. A retrospective study","volume":"203","author":"LE Lins","year":"1978","journal-title":"Acta Med Scand"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/clc.4960110607","article-title":"Reliability of QT intervals as indicators of clinical hypercalcemia","volume":"11","author":"R Ahmed","year":"1988","journal-title":"Clin Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3810\/pgm.2004.04.1486","article-title":"Understanding hypercalcemia. Its metabolic basis, signs, and symptoms","volume":"115","author":"SE Inzucchi","year":"2004","journal-title":"Postgrad Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e017703","DOI":"10.1136\/bmjopen-2017-017703","article-title":"Should total calcium be adjusted for albumin? A retrospective observational study of laboratory data from central Norway","volume":"8","author":"IA Lian","year":"2018","journal-title":"BMJ Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/01.CCM.0000063044.55669.3C","article-title":"Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill","volume":"31","author":"J Slomp","year":"2003","journal-title":"Crit Care Med"},{"key":"ref16","first-page":"680","article-title":"Mechanisms of cancer-induced hypercalcemia","volume":"67","author":"TJ Rosol","year":"1992","journal-title":"Lab Invest"},{"key":"ref17","first-page":"473","article-title":"Rehydration in the treatment of severe hypercalcaemia","volume":"50","author":"DJ Hosking","year":"1981","journal-title":"Q J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archinte.1991.00400030039007","article-title":"Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group","volume":"151","author":"FR Singer","year":"1991","journal-title":"Arch Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1001\/archinte.154.17.1935","article-title":"Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"R Gucalp","year":"1994","journal-title":"Arch Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1080\/10428194.2022.2115840","article-title":"Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma","volume":"63","author":"MM Lei","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref21","first-page":"2375","article-title":"Calcitonine humaine dans les hypercalc\u00e9mies n\u00e9oplasiques. R\u00e9sultats d'un essai prospectif randomis\u00e9 [Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial]","volume":"17","author":"B Chevallier","year":"1988","journal-title":"Presse Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4158\/EP.15.3.234","article-title":"Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone-related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma","volume":"15","author":"SB Shivnani","year":"2009","journal-title":"Endocr Pract"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2201-6428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:52:45Z","timestamp":1730825565000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2201-6428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":22,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2024,2,8]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2201-6428","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}